Look up one drug

Reason for Use code 186 For acute treatment of deep venous thrombosis (DVT), for a maximum of three weeks; Coverage limit: LU Authorization Period: 1 year Reason for Use code 187 For DVT in pregnant or lactating females; Coverage limit: LU Authorization Period: 1 year Reason for Use code 188 For DVT in patients whom treatment with warfarin is not tolerated, or contraindicated; Coverage limit: LU Authorization Period: 1 year Reason for Use code 189 For DVT in patients who have failed treatment with warfarin. Coverage limit: LU Authorization Period: 1 year Reason for Use code 323 For the acute treatment of pulmonary embolism, maximum of three weeks. Coverage limit: LU Authorization Period: 1 year Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Tinzaparin Brand(s): Innohep DOSAGE FORM/ STRENGTH: Check formulary or e-formulary for funded products For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin. Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after surgery. For post-operative prophylaxis of DVT for patients who had hip or knee surgery, and cannot use warfarin. Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 29, record 8, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Tinzaparin Brand(s): Innohep DOSAGE FORM/ STRENGTH: 2,500 IU, 3,500 IU, 4,500 IU, 8,000 IU, 10,000 IU, 12,000 IU, 14,000 IU, 16,000 IU, 18,000 IU, 20,000 IU Injection 1. For peri-operative bridging for patients who require long-term warfarin therapy and must temporarily discontinue it before and after surgery, and who are at moderate- to high-risk for an embolic event while off warfarin., Standard Approval Duration: As requested up to a maximum of 10 days before the date of surgery plus up to 7 days after the date of hospital discharge 2. For post-operative prophylaxis of DVT for patients who had hip or knee surgery and cannot use warfarin. 10 Standard Approval Duration: As requested up to a maximum of 30 days starting on the day of surgery. 3. For the post-operative prophylaxis of venous thromboembolism following abdominal or pelvic surgery for cancer in patients who do not have a history of or risk factors for heparin-induced thrombocytopenia. Standard Approval Duration: Maximum of 30 days. 470 Oral Hypoglycemic Agents Note: Prescribers do not need to make an EAP request for patients currently receiving pioglitazone or rosiglitazone through ODB. Physicians will be required to make an application for coverage for any patient new to ODB that is being started on either of these drugs or any ODB recipient who is new to using these drugs. Requests for ongoing treatment with pioglitazone or rosiglitazone for patients who were previously covered by other means may be considered according to renewal criteria. Funding under the EAP for pioglitazone or rosiglitazone will not be provided in the following clinical settings: • Patients with type 1 diabetes • Monotherapy, even if patient is intolerant or has contraindications to both metformin and sulfonlyureas • Combination use with either nitrates or insulin • Patients with any stage of heart failure (NYHA Class I, II, III, IV) • Patients at high risk for bone fracture (post-menopausal women with previously confirmed osteoporosis or osteopenia) • Patients with recent history (in the past 3 months) of ischemic cardiovascular event (myocardial infarction, unstable angina) • Patients with active bladder cancer, a history of bladder cancer or uninvestigated macroscopic haematuria EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 470, record 309, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Innohep · DIN 09857367 Manufacturer: Leo Pharma Inc.; listing date 2010-07-20 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

DIN 09857367: Innohep Raw flags: sec12=Y, sec3=Y Item: 201200081; group id 262; item number 0512; lccId 00048; manufacturer id LEO Source form: Inj Pref Syr; strength: 2500IU/0.25mL Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $7.3042; ministry $7.3042 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09857367 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Shortage status: not checked (no credentials)